Hirsch and Poller's1 article in the February 14, 1994, issue of the Archives contains a protocol of subcutaneous phytonadione to reverse warfarin overanticoagulation. They referenced an article that appeared in Chest in 1992.2 The article contained an intravenous phytonadione protocol. We would like to know the rationale for the change in the route of administration. Are both routes equally effective?
Kelliher AF, Alexis G. Phytonadione Route of Administration for Warfarin Overanticoagulation Reversal. Arch Intern Med. 1995;155(9):990. doi:10.1001/archinte.1995.00430090142017
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: